"We are excited about our acquisition of the U.S. rights to Promensil and Trinovin, said Wayne M. Bos, president and CEO, Natrol. This acquisition expands Natrol's product reach and capabilities with extensive science that will leverage our promise to provide premium benefits to our customers with quality and reliability. We will capitalize on our strengths in operations, marketing, sales and distribution to build upon the market presence already established for these brands."
Christopher Naughton, CEO, Novogen, said, "Novogen is extremely pleased to have secured Natrol as its exclusive licensee for Promensil and Trinovin in the U.S. Natrol brings marketing expertise and the product critical mass that will enable the premium brands Promensil and Trinovin to be elevated to their potential in the U.S. marketplace."